Kura Oncology, Inc. (KURA)
12.40
+0.51
(+4.29%)
USD |
NASDAQ |
Aug 24, 16:00
13.12
+0.72
(+5.81%)
After-Hours: 20:00
Kura Oncology Shareholders Equity (Quarterly) : 48.43M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 48.43M |
| March 31, 2026 | 107.88M |
| December 31, 2025 | 174.14M |
| September 30, 2025 | 242.54M |
| June 30, 2025 | 305.49M |
| March 31, 2025 | 364.41M |
| December 31, 2024 | 413.64M |
| September 30, 2024 | 423.77M |
| June 30, 2024 | 466.07M |
| March 31, 2024 | 505.08M |
| December 31, 2023 | 397.27M |
| September 30, 2023 | 429.94M |
| June 30, 2023 | 459.68M |
| March 31, 2023 | 395.18M |
| December 31, 2022 | 420.28M |
| September 30, 2022 | 419.62M |
| June 30, 2022 | 449.49M |
| March 31, 2022 | 476.25M |
| December 31, 2021 | 506.61M |
| September 30, 2021 | 533.76M |
| June 30, 2021 | 558.55M |
| March 31, 2021 | 585.99M |
| December 31, 2020 | 610.90M |
| Date | Value |
|---|---|
| September 30, 2020 | 306.50M |
| June 30, 2020 | 322.37M |
| March 31, 2020 | 203.20M |
| December 31, 2019 | 218.78M |
| September 30, 2019 | 233.58M |
| June 30, 2019 | 246.58M |
| March 31, 2019 | 149.56M |
| December 31, 2018 | 160.98M |
| September 30, 2018 | 174.61M |
| June 30, 2018 | 112.40M |
| March 31, 2018 | 124.80M |
| December 31, 2017 | 79.86M |
| September 30, 2017 | 89.20M |
| June 30, 2017 | 43.64M |
| March 31, 2017 | 50.24M |
| December 31, 2016 | 56.88M |
| September 30, 2016 | 63.67M |
| June 30, 2016 | 70.04M |
| March 31, 2016 | 76.07M |
| December 31, 2015 | 82.10M |
| September 30, 2015 | 37.78M |
| June 30, 2015 | 43.32M |
| March 31, 2015 | 48.89M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | 4.371M |
| Fortress Biotech, Inc. | 164.14M |
| Syndax Pharmaceuticals, Inc. | 15.10M |
| Spero Therapeutics, Inc. | 44.20M |
| Gossamer Bio, Inc. | -94.03M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 587.79M |
| Total Liabilities (Quarterly) | 539.36M |
| Debt to Equity Ratio | 0.5049 |
| Current Ratio | 4.733 |
| Net Debt Paydown Yield | -0.10% |